Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMED M MILHEM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558429100
CMS profile
806076
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $53.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMED M MILHEM

NPI 1558429100 · CMS profile ID 806076

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $53.1804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242511626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,538.13 7
PY2021 $18.12 2
PY2022 $21.70 2
PY2025 $53.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,472.81 4
PY2025 Principal investigator $581,246.58 77
PY2024 Principal investigator $999,952.01 109
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $827,610.63 137
PY2022 Principal investigator $1,233,503.31 110
PY2021 Principal investigator $751,345.38 31
PY2020 Principal investigator $896,218.13 99
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,105,673.41 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

110 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $51,713.26 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 940403739
Principal investigator 1 Merck Sharp & Dohme LLC $3,994.50 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 940403741
Principal investigator 1 Merck Sharp & Dohme LLC $3.05 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 940403785
Principal investigator 1 Merck Sharp & Dohme LLC $0.13 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Epacadostat or Placebo in Combination With Pembrolizumab in Subjects with Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 940406349
Principal investigator 1 Merck Sharp & Dohme LLC $5,860.15 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 940408131
Principal investigator 1 Merck Sharp & Dohme LLC $161,202.88 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 940408133
Principal investigator 1 Merck Sharp & Dohme LLC $6,248.30 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 940409205
Principal investigator 1 Merck Sharp & Dohme LLC $1,985.73 12/31/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 940409207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,255.02 12/14/2022 Non-covered Recipient Entity
State University Of Iowa
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications No dispute reported 06/30/2026 933188021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,655.24 12/14/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612267
Principal investigator 1 PFIZER INC. $1,524.60 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776481
Principal investigator 1 PFIZER INC. $350.00 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776609
Principal investigator 1 PFIZER INC. $350.00 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776611
Principal investigator 1 PFIZER INC. $1,738.80 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776699
Principal investigator 1 PFIZER INC. $2,425.80 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776825
Principal investigator 1 PFIZER INC. $350.00 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777389
Principal investigator 1 PFIZER INC. $350.00 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777399
Principal investigator 1 PFIZER INC. $280.00 12/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777431
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,046.05 11/25/2022 Non-covered Recipient Entity
Medical University Of South Carolina
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications No dispute reported 06/30/2026 933188005
Principal investigator 1 PFIZER INC. $15,642.90 11/25/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777965
Principal investigator 1 GlaxoSmithKline, LLC. $335.00 11/18/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934079
Principal investigator 1 PFIZER INC. $4,035.50 11/10/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777607
Principal investigator 1 PFIZER INC. $762.30 11/10/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777609
Principal investigator 1 PFIZER INC. $1,524.60 11/10/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777667
Principal investigator 1 PFIZER INC. $5,336.10 11/10/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777669
Principal investigator 1 PFIZER INC. $1,524.60 11/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777799
Principal investigator 1 Merck Sharp & Dohme LLC $35,834.00 10/24/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 940408091
Principal investigator 1 GlaxoSmithKline, LLC. $181.00 10/21/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934073
Principal investigator 1 PFIZER INC. $200,073.80 10/13/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777225
Principal investigator 1 PFIZER INC. $159,731.60 10/13/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777433
Principal investigator 1 PFIZER INC. $5,000.00 10/11/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949776613
Principal investigator 1 PFIZER INC. $43,884.26 10/11/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777631
Principal investigator 1 PFIZER INC. $1,000.00 10/11/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949777801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $204,801.53 10/05/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612255
Principal investigator 1 PFIZER INC. $1,953.00 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790123
Principal investigator 1 PFIZER INC. $4,668.30 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949791021
Principal investigator 1 PFIZER INC. $3,049.20 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949791023
Principal investigator 1 PFIZER INC. $2,286.90 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949792061
Principal investigator 1 PFIZER INC. $4,920.30 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949792075
Principal investigator 1 PFIZER INC. $9,210.60 09/27/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949792077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,343.11 09/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,721.06 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,567.44 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,567.44 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,567.44 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,567.44 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $111.77 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,721.16 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 09/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612245
Principal investigator 1 Merck Sharp & Dohme LLC $7,136.20 09/18/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 940403783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,675.92 09/16/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,289.42 09/16/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612219
Principal investigator 1 PFIZER INC. $1,524.60 09/15/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790055
Principal investigator 1 PFIZER INC. $6,231.90 09/15/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790121
Principal investigator 1 Amgen Inc. $57,074.04 09/14/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas No dispute reported 06/30/2026 942841703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.00 08/26/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612213
Principal investigator 1 PFIZER INC. $12,909.40 08/25/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949791877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.80 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,772.00 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.00 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,827.00 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.66 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.60 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $321.30 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $321.30 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.12 08/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $876.67 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $321.30 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,230.64 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $559.68 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $144.90 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,575.00 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.54 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.66 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.60 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $321.30 08/19/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 938612179
Principal investigator 1 Merck Sharp & Dohme LLC $19,905.80 07/29/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 940409763
Principal investigator 1 GlaxoSmithKline, LLC. $3,152.00 07/27/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934081
Principal investigator 1 Genentech, Inc. $1,500.00 06/23/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731337
Principal investigator 1 Genentech, Inc. $5,000.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731343
Principal investigator 1 Genentech, Inc. $1,500.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731349
Principal investigator 1 Genentech, Inc. $1,125.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731353
Principal investigator 1 Genentech, Inc. $18,137.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731359
Principal investigator 1 Genentech, Inc. $5,613.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731365
Principal investigator 1 Genentech, Inc. $2,225.00 06/21/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS No dispute reported 06/30/2026 950731371
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,492.96 05/26/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
MRD Monotherapy, combination of VSV GP w antiPD1 No dispute reported 06/30/2026 965577439
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 05/18/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934069
Principal investigator 1 GlaxoSmithKline, LLC. $1,159.00 04/25/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934075
Principal investigator 1 PFIZER INC. $1,430.10 03/29/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790341
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 03/25/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934071
Principal investigator 1 PFIZER INC. $6,350.00 03/22/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790427
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,200.00 03/15/2022 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Dose Escalation ofDF6002in Patients With Advanced Solid Tumors, and Expansion in Selected Indications No dispute reported 06/30/2026 933188049
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/25/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934077
Principal investigator 1 PFIZER INC. $1,500.00 02/24/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790357
Principal investigator 1 PFIZER INC. $2,000.00 02/24/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790423
Principal investigator 1 PFIZER INC. $850.00 02/24/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 949790425
Principal investigator 1 GlaxoSmithKline, LLC. $287.00 01/26/2022 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 943934067